Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
This NIH/National Cancer Institute R01 funds academic-industrial partnerships to translate and validate in vivo imaging, data science, or spectroscopic technologies into tools for cancer and other …
- Deadline
- Jan 7, 2027
- Posted
- Nov 6, 2024
- Award amount
- Up to $500,000
Don’t miss this deadline
We’ll email you before Jan 7, 2027 so you have time to apply.
In plain English
This NIH/National Cancer Institute R01 funds academic-industrial partnerships to translate and validate in vivo imaging, data science, or spectroscopic technologies into tools for cancer and other diseases; a clinical trial is optional. Eligible applicants include universities, research institutions, and tribal and community organizations, and foreign organizations are listed among eligible applicants. The award maximum is about $500,000, and the model assumes an academic-industry collaboration. It is aimed at research teams.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Education and Health — soonest deadline first.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Jan 7, 2027
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 8 days
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
National Institutes of Health · Up to $250K · Due in 8 days
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 8 days
Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
National Institutes of Health · Amount varies · Due in 24 days
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 30 days
Also listed under National Institutes of Health, Education Grants and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.